Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset ...
The Swiss drugmaker reported a phase 3 win for fenebrutinib over Sanofi's Aubagio in RMS in November. In that study, Roche linked its drug candidate to a 59% reduction in the annualized relapse rate ...
Liver-related side effects have led some analysts to question fenebrutinib’s prospects, even though the drug has now cleared ...
RHHBY's fenebrutinib slashes RMS relapses by 51% in phase III, advancing its bid for a first high-efficacy oral therapy in MS ...
Zealand Pharma’s shares fell 32% in early morning trading Friday after its Roche-partnered asset petrelintide failed to meet investor expectations in a mid-stage clinical trial.
Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases. Highlights included presentations from the ongoing ...
FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...
Roche Holding AG RHHBY announced positive top-line data from a mid-stage study of its investigational candidate, CT-388, being developed for the treatment of obesity. CT-388 is a once-weekly ...
CT-388 demonstrated significant placebo-adjusted weight loss at 48 weeks, with no plateau, in a Phase II trial for obesity treatment. The investigational therapy selectively activates GLP-1 and GIP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results